Market Overview

The Bull Thesis For Merck Is Evaporating

The Bull Thesis For Merck Is Evaporating
Related MRK
Gabelli Names Clovis As Top Pick, Calls The Biotech A Likely Takeout Candidate
The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings
Roche Gains FDA Approval In Front-Line NSCLC, But The Biggest Battle Still Lies Ahead (Seeking Alpha)

The bullish case for Merck & Co., Inc. (NYSE: MRK) has been "derailed" after the company signaled to investors last week a longer-than-expected delay in a key lung cancer trial for its Keytruda therapy. Morgan Stanley's David Risinger downgrades Merck's stock rating from Overweight to Equal-Weight with a price target slashed from $69 to $56.

Many investors were working on the assumption that Merck's first-line lung cancer trial called Keynote 189 would see success in early 2018, the analyst wrote. However, the company guided to a new primary completion date for February 2019 with no clarity on any interim look timing although any interim look in 2018 will likely be successful.

On top of that, the company also pulled its first-line Keytruda chemo combo lung cancer application in Europe.

In the meantime, Merck's competition could win the race to report first-line lung cancer phase 3 results first, the analyst also wrote. Specifically, Bristol-Myers Squibb Co (NYSE: BMY) is expected to report two segments of its CheckMate-227 in the first half of 2018. Roche Holding Ltd. (ADR) (OTCM: RHHBY) is also expected to report first-line lung cancer trial results in the first half of 2018 from its IMpower 150.

Finally, Merck's Keytruda update prompted the analyst to make the following revisions to his estimates:

  • 2018 EPS lowered from $4.04 to $4.00.
  • 2019 EPS lowered from $4.34 to $4.17.
  • 2020 EPS lowered from $4.80 to $4.54.
  • Long-term EPS compounded annual growth rate from 6.7 percent to 5.4 percent.

At time of publication, shares of Merck were down 4.94 percent at $55.40.

Related Links:

5 Biggest Price Target Changes For Monday

Healthcare ETFs Set To Soar As Q3 Earnings Unfold

Latest Ratings for MRK

Nov 2018CitigroupMaintainsBuyBuy
Oct 2018CitigroupMaintainsBuyBuy
Oct 2018SunTrust Robinson HumphreyMaintainsBuyBuy

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech News Downgrades Price Target FDA Analyst Ratings Movers Best of Benzinga


Related Articles (BMY + MRK)

View Comments and Join the Discussion!

Latest Ratings

TVPTImperial CapitalDowngrades15.8
ACORGoldman SachsDowngrades10.0
BCOVB. Riley FBRUpgrades12.0
CAMPFirst AnalysisDowngrades22.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Insider Weekends – 5 Big Insider Buys And Sells From The Week Of October 23

Apple Continues Spectacular Pre-Earnings Rally, Nears $170